Clarity Pharmaceuticals Ltd has released a press release.
Quarterly Activity Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Dosimetry Recruitment of theranostic prostate trial complete
- Appendix 4C Cash Flow Report
- Recruitment closed on C-BOBCAT SAR-Bombesin trial
- App 4E Preliminary Final Report 30 June 2021
Later from Clarity Pharmaceuticals
- Managing Directors Presentation to Annual General Meeting
- SARTATE Neuroblastoma trial advances to cohort 2
- Clarity receives $3.26 million R&D tax incentive refund
- US FDA Study May Proceed letter for Cu-64 SAR-bisPSMA
- First patient treated in cohort 2 neuroblastoma trial
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals